Table 6.
Effect of cannabis on eCB levels.
| OEA | PEA | 2AG | AA | AEA | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Before | After | Before | After | Before | After | Before | After | Before | After | |
| UC Cannabis | 16.3 ± 3.9 | 18.9 ± 2.35 | 4.2 ± 0.8 | 4.6 ± 0.5 | 10.6 ± 1.9 | 10.2 ± 2.7 | 3,806.7 ± 930 | 3,778.2 ± 607 | 460.5 ± 109 | 386.1 ± 62.8 |
| UC Placebo | 21.2 ± 2.3 | 16.9 ± 1.92 | 4.8 ± 0.2 | 3.2 ± 0.3* | 13.6 ± 3.9 | 12.3 ± 3.9 | 4,552.6 ± 536 | 2,774.3 ± 411* | 628.2 ± 62 | 422.9* ± 63.3 |
| CD Cannabis | 23.0 ± 3 | 22.8 ± 2.5 | 5.6 ± 0.7 | 5.1 ± 0.6 | 37.9 ± 7.5 | 32.6 ± 11.6 | 7,553.2 ± 1,785 | 4,943.1 ± 682 | 710.1 ± 94.3 | 737.1 ± 103 |
| CD Placebo | 27.3 ± 2.4 | 25.4 ± 3.3 | 5.1 ± 0.5 | 4.5 ± 0.5 | 37.9 ± 9.1 | 49.9 ± 12.7 | 7,957.7 ± 965 | 6,057 ± 661 | 822.3 ± 121 | 674.9 ± 59 |
The effect of cannabis and placebo treatment on eCB level in the sera of IBD patients. UC and CD patients were treated for 8 weeks with cannabis or placebo. One week before the beginning of the experiment and 8 weeks later, blood was taken from the patients, and eCB levels were evaluated in the sera by using LC-MS/MS. eCB levels are in pmol/ml.
*Levels of eCBs before and after cannabis/placebo use are significantly different, p < 0.05.